<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">EUROPEAN SYNCHROTRON RADIATION FACILITY</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
				</availability>
				<date type="published" when="2009-02-27">27 February 2009</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Hélène</forename><surname>Elleaume</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Elleaume</forename><surname>Hélène</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Adam</forename><forename type="middle">Jean</forename><surname>François</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Besse</forename><surname>Sébastien</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bobyk</forename><surname>Laure</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Edouard</forename><surname>Magali</surname></persName>
						</author>
						<author>
							<persName><roleName>Pr</roleName><forename type="first">Esteve</forename><surname>François</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pierre</forename><surname>Deman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mathias</forename><surname>Vautrin</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Smilowitz</forename><surname>Henry</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Equipe 6 Grenoble -Institute of Neuroscience ID17 Medical Beamline E</orgName>
								<orgName type="laboratory">Laboratory INSERM U836</orgName>
								<address>
									<postBox>S.R.F. BP 220</postBox>
									<postCode>38043 -</postCode>
									<settlement>Grenoble</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Medical Department Upton</orgName>
								<orgName type="laboratory">DILMANIAN Avraham Laboratory Brookhaven National Laboratory</orgName>
								<address>
									<addrLine>Bld 490</addrLine>
									<postCode>11973-5000</postCode>
									<settlement>New york</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Dept of Pharmacology</orgName>
								<orgName type="laboratory">Laboratory</orgName>
								<orgName type="institution">University of Connecticut Health Center</orgName>
								<address>
									<addrLine>263 Farmington Ave. Farmington</addrLine>
									<postCode>06030</postCode>
									<region>CT</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Jean LAISSUE Laboratory Institute of Pathology</orgName>
								<orgName type="institution">University of Bern</orgName>
								<address>
									<addrLine>Murtenstrasse 31</addrLine>
									<postBox>P.O. 62 CH- 3010</postBox>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution">BERN Switzerland. Jim HAINFELD Laboratory NANOPROBES</orgName>
								<address>
									<addrLine>95 Horseblock Road Yaphank</addrLine>
									<postCode>11980-9710</postCode>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">EUROPEAN SYNCHROTRON RADIATION FACILITY</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2009-02-27">27 February 2009</date>
						</imprint>
					</monogr>
					<idno type="MD5">D8574E9F6831BD2EE45677BCE88308C0</idno>
					<note type="submission">from: Feb 2 nd 2009 to: Feb 7 th 2009</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-05-22T19:58+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">unknown</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=1, consolidateHeader=1, consolidateFunders=0, includeRawAffiliations=false, includeRawCitations=true, includeRawCopyrights=false, generateTeiIds=false, generateTeiCoordinates=[], flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Gold concentration vs time</head><p>y = 24.781e -0.0071x R 2 = 0.9807 y = 20.209e -0.0085x R 2 = 0.9962 0 5 10 15 20 25 30 0 20 40 60 80 100 120 140 160 Time [min] Gold Concentration [mg/ml]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Aim:</head><p>The purpose of this study was to determine whether the efficacy of heavy-atom-enhanced Synchrotron Stereotactic Radiotherapy (SSR) could be improved in the F98 rodent glioma model, by using gold nanoparticles injected intra cerebrally by convection-enhanced delivery methods.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Preliminary results (MD355):</head><p>We carried out a preliminary study in February 2009, using intracerebral nanoparticles delivery in association with synchrotron Stereotactic radiotherapy for the treatment of F98 glioma bearing rats. We do not have the final results of this study since the animals have been treated only one month ago. However, we have obtained important information regarding the gold nanoparticles bio-distribution, toxicity and preliminary survival results.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Imaging -Gold quantification:</head><p>Two rats bearing F98 glioma were imaged with 3D computed tomography every 10 min for more than 2 hours to determine the gold nanoparticles bio-distribution after intracerebral delivery with convectionenhanced delivery. From the CT imaging it is possible to quantify the intracerebral gold concentration. The gold nanoparticles were infused in 20 µL of PBS over 40 minutes (Au concentration: 100 mg/mL). This experiment demonstrate that very high concentrations of gold nanoparticles could be obtained in the rats' brains for a long duration, suitable for gold-enhanced radiotherapy. However the toxicity was important after intracerebral infusion of gold at this concentration and we had to decrease the amount of gold nanoparticles injected for the therapy experiment. The concentration was divided by 2 and the infused volume was also decreased (5 µL instead of 20 µL).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A) B)</head><p>Figure1: A) Gold distribution in a F98 glioma bearing rats 10 min after gold nanoparticles intra tumoral delivery. B) Gold concentration versus time measured over time in two animals</p></div>		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Therapy study:</head><p>The rats were divided into 4 experimental groups: "untreated animals", "irradiation alone 15 Gy delivered in a single fraction", "Gold alone", "Gold + irradiation". For all irradiated groups, the irradiation was performed on day 14. The gold nanoparticles were injected into the tumor by convection-enhanced delivery methods few minutes before irradiation (Gold nanoparticles concentration 50 mg/mL -5 µL infused by convection-enhanced delvery at a rate 0.5 µL/min).</p><p>Tumor imaging: All rats were imaged at the ESRF on day 14 th after tumor inoculation with monochromatic computed tomography at ID17 after injection of a contrast agent intravenously for assessing the tumor presence.</p><p>The irradiation setup, described in the previous publications <ref type="bibr" target="#b0">(Adam 2003)</ref>, was used. The rats were positioned vertically and irradiated in stereotactic conditions with the beam restricted to the tumor dimensions with monochromatic x-rays tuned above the gold K-edge .</p><p>The preliminary survival rates, as currently available, are reported in </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions:</head><p>Encouraging results were obtained and we would like to further investigate the therapeutic efficacy of this treatment. We do not have the final results of this study since the animals have been treated only one month ago. However, we have obtained important information regarding the gold nanoparticles bio-distribution, toxicity and preliminary survival results.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Synchrotron radiation therapy of malignant brain glioma loaded with an iodinated contrast agent: First trial on rats bearing F98 gliomas</title>
		<author>
			<persName><forename type="first">Jean-François</forename><surname>Adam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hélène</forename><surname>Elleaume</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aurélie</forename><surname>Joubert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marie-Claude</forename><surname>Biston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anne-Marie</forename><surname>Charvet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jacques</forename><surname>Balosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jean-François</forename><surname>Le Bas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">François</forename><surname>Estève</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijrobp.2003.07.007</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Radiation Oncology*Biology*Physics</title>
		<title level="j" type="abbrev">International Journal of Radiation Oncology*Biology*Physics</title>
		<idno type="ISSN">0360-3016</idno>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1413" to="1426" />
			<date type="published" when="2003-12">2003</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Adam J.F., Elleaume H., Joubert A., et al. Synchrotron radiation therapy of malignant brain glioma loaded with an iodinated contrast agent: first trial on rats bearing F98 gliomas. Int J Radiat Oncol Biol Phys 2003; 57(5): 1413-1426.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
